阿托伐他汀联合水化预防慢性肾功能不全患者造影剂肾病的研究  

The study of atorvastatin combined with hydration to prevent contrast-induced nephropathy

作　　者：张晓波[1] 唐凤英[1] 王桂花[1] 张丽琴[1] 杨伟伟[1] 季小琪[1] 

机构地区：[1]南京医科大学附属淮安第一人民医院肾内科,223300

出　　处：《中华全科医师杂志》2011年第4期258-259,共2页Chinese Journal of General Practitioners

摘　　要：探讨阿托伐他汀联合水化对原有慢性肾功能不全患者出现造影剂肾病的预防作用。100例原有慢性肾功能不全患者造影术后随机分为单纯水化组（51例）和阿托伐他汀联合水化组（49例），测定造影前后48h血肌酐水平。试验组造影剂肾病发生率显著低于对照组[8％（5／41）比24％（12／49）（P〈0．05）]。提示，阿托伐他汀联合水化可预防原有慢性肾功能不全患者造影剂肾病的发生。One hundred patients with chronic renal failure（CRF） undergoing contrast diagnosis and/ or interventional therapy were randomly divided into two groups： patients in hydration alone group（ n = 49 ） received intravenous infusion of 0. 9% sodium chloride 12 h before injection of contrast media till 12 h after examination （hydration）, patients in atorvastatin plus hydration group （n = 51 ） received atorvastatin 80 mg/d 24 h before examintion for 3 d in addition to hydration. The serum ereatinine concentrations were measured before and 48 h after injection of contrast media. In atorvastatin plus hydration group, the incidence rate of contrast-lnduced nephropathy （CIN） was 8% （4/51） , which was significantly lower than that of hydration group （24%, 12/49） （P 〈 0. 05 ）. Short-term and large dose administration of atorvastatin plus hydration can decrease the incidence of CIN in patients with chronic renal failure undergoing contrast diagnosis and/or interventional thrapy.

关 键 词：肾病 降血脂药 

分 类 号：R692.5[医药卫生—泌尿科学]